Gilead Sciences | GILD - Debt


Gilead Sciences reported $24.94B in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 39.43M 982K Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Moderna USD 1.31B 571M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026